Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Cancer Cytopathol. 2020 Nov 19;129(4):318–325. doi: 10.1002/cncy.22388

TABLE 4.

Clinical Outcomes and Proportion of High-Grade Component in Primary Tumor (n = 16)

High-Grade Component Recurrence or Metastasis, n
Patient Outcome, n
Yes No Alive Without Disease Alive With Disease Dead With Disease
0%-10% 1 3 3 0 1
>10%-50% 2 3 2 1 2
>50%-100% 5 2 1 3 3

The median follow-up was 6.8 months. The proportion of high-grade component was calculated on the resection specimen.